Compare Crispr Therapeutics AG (CRSP) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ON Holding AG — how do they compare? Crispr Therapeutics AG trades at $53.77 (market cap $5.23B), while ON Holding AG trades at $31 (market cap $10.33B). The key difference: ON Holding AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| CRSP | ONON | |
|---|---|---|
Market Cap | $5.23B | $10.33B |
Sector | Health | Technology |
52-Week High | $76.78 | $50.63 |
52-Week Low | $44.34 | $30.91 |
Enterprise Value | $3.65B | $9.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
ONON shares plunged 19.52% to $31.21 after Q2 2026 earnings revealed a rare revenue miss and reduced full-year growth guidance, despite beating EPS estimates. The stock now trades near key support at $30 with bearish technical indicators dominating. Fundamentally, the company maintains strong profitability with 64.82% gross margins and 23.95% ROE, but wholesale channel weakness and cautious consumer spending have tempered growth expectations.
While current valuation multiples appear reasonable (P/E 21.17, P/S 5), the stock faces near-term headwinds from growth deceleration. Analyst consensus remains bullish with a $52.86 price target representing 69% upside, but investors should monitor Q3 earnings execution and wholesale recovery for confirmation of the investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
